lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network

Frontiers in Genetics - Switzerland
doi 10.3389/fgene.2019.00850
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature With Predictive and Prognostic Value

Cancer Research
Cancer ResearchOncology
2016English

Integrated Analysis of Co‐expression and ceRNA Network Identifies Five lncRNAs as Prognostic Markers for Breast Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Comprehensive Analysis of the Aberrantly Expressed lncRNA‑associated ceRNA Network in Breast Cancer

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2019English

TLR5: A Prognostic and Monitoring Indicator for Triple-Negative Breast Cancer

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2019English

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Prognostic Genes of Triple‑negative Breast Cancer Identified by Weighted Gene Co‑expression Network Analysis

Oncology Letters
Cancer ResearchOncology
2019English

Platinum-Based Therapy for Triple-Negative Breast Cancer Treatment: A Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Integrative Analysis of lncRNAs and miRNAs With Coding RNAs Associated With ceRNA Crosstalk Network in Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

The Clinical Prognostic Value of lncRNA FAM83H-AS1 in Cancer Patients: A Meta-Analysis

Cancer Cell International
Cancer ResearchOncologyGenetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy